CAPRICOR THERAPEUTICS, INC. (NASDAQ:CAPR) Files An 8-K Other Events
Item 8.01 Other Events.
On July 15, 2019, Capricor Therapeutics, Inc. (the “Company”) announced that a pre-specified interim analysis performed on the HOPE-2 trial showed statistically significant improvements across several independent clinical measures including the PUL 2.0. HOPE-2 is a randomized, double-blind, placebo-controlled, Phase II clinical trial of CAP-1002 (allogeneic cardiosphere-derived cells) in steroid-treated boys and young men who are in advanced stages of Duchenne muscular dystrophy. Capricor will continue its ongoing discussions with the FDA about the DMD program and future plans.
Item 9.01. Financial Statements and Exhibits.
| 99.1 | Press Release issued by Capricor Therapeutics, Inc. on July 15, 2019, providing update on HOPE-2 trial. |
CAPRICOR THERAPEUTICS, INC. Exhibit
EX-99.1 2 tv525181_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Capricor Therapeutics Announces Positive Results from its Interim Analysis in the HOPE-2 Trial to Treat Patients with Duchenne Muscular Dystrophy –Interim Analysis Showed Statistically Significant Improvements in the Performance of the Upper Limb,…
To view the full exhibit click here
About CAPRICOR THERAPEUTICS, INC. (NASDAQ:CAPR)
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. Its product candidate, CAP-1002, a cardiosphere-derived cell product, is being tested in the ALLSTAR Phase II clinical study on patients having suffered a myocardial infarction (MI), while the DYNAMIC clinical study is testing CAP-1002 in patients in the advanced-stage of heart failure. CAP-1002 is also being tested in the HOPE-Duchenne Phase I/II clinical study for use in connection with Duchenne muscular dystrophy-related cardiomyopathy. Cenderitide, a dual receptor natriuretic peptide agonist, is being tested in a Phase II clinical study. Exosomes are nano-sized, membrane-enclosed vesicles.
